Urs Hagemann
Company: Bayer
Job title: Laboratory Head
Bio:
- Ained biologist (University of Freiburg, Germany) with PhD rer. nat. in protein engineering
- Ten years of experience in the pharmaceutical industry from early drug discovery to clinical development in oncology
- Since 2012, focusing on the development of targeted alpha emitting radiopharmaceuticals
- Proven track record in antibody-based therapeutics including radiopharmaceuticials
Seminars:
Panel Discussion: Are Targeted Alpha Emitting Therapies the Endgame of Radiopharmaceutical Progress? 3:00 pm
Join a panel of experts to discuss: What could improve Alpha emitting isotopes further? What new oncological and non-oncological diseases can we target next? Have Beta-emitting therapies have reached their maximum potential?Read more
day: Day One
Targeted Thorium-227 Conjugates – Exploring the potential of Bayer’s’ novel targeted alpha therapy platform in solid tumors 2:00 pm
Learn Targeted thorium-227 conjugates (TTCs) represent a new class of molecules for targeted alpha therapy (TAT) The covalent attachment of a 3,2-HOPO chelator to targeting moieties ( e.g. tumor antigen targeting antibodies) enables specific complexation and delivery of the alpha particle emitter thorium-227 to tumor cells Due to the high linear energy transfer and short…Read more
day: Day One